<DOC>
	<DOCNO>NCT00397228</DOCNO>
	<brief_summary>After screen evaluation include baseline clinical laboratory testing , physical neurological evaluation , subject ask undergo injection ALTROPANE® follow 60 minute serial dynamic imaging . Subjects undergo second injection ALTROPANE® follow 60 minute serial dynamic imaging within 2-6 week injection 1 .</brief_summary>
	<brief_title>ALTROPANE® SPECT Imaging Patients With Parkinson Disease</brief_title>
	<detailed_description>The underlying goal open label image study optimize image outcome ALTROPANE® mild moderate PD subject . All study procedure conduct Institute Neurodegenerative Disorders ( IND ) Molecular NeuroImaging ( MNI ) New Haven , CT . Subjects PD ( n=15 ) recruit undergo ALTROPANE® SPECT . All subject undergo write informed consent screen evaluation include baseline clinical laboratory testing , physical neurological evaluation . Subjects ask undergo injection ALTROPANE® follow 60 minute serial dynamic imaging . Subjects ask undergo second image visit two-six week follow initial image visit ass reproducibility image outcome . The imaging analyse perform image-processing specialist remain mask clinical severity . The primary imaging outcome measure brain regional distribution volume express target region occipital ratio . Striatal region interest caudate putamen define placement standardize base previously optimize region placement protocol . Imaging data also analyze use automate objective striatal analysis software package .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<criteria>The participant 30 year old time PD diagnosis . Written inform consent obtain . Participants clinical diagnosis idiopathic Parkinson 's disease &lt; 7 year . Hoehn Yahr stag IIII . Negative drug screen The participant atypical druginduced Parkinson 's disease . The participant dementia . The participant clinically significant clinical laboratory value and/or clinically significant unstable medical psychiatric illness . Treatment within six month prior screen bupropion , methylphenidate , reserpine , alpha methyldopa , amphetamine . The participant history alcohol , narcotic , drug abuse within past 2 year . The participant receive investigational drug within 60 day screen visit . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Parkinson</keyword>
	<keyword>image</keyword>
	<keyword>dopamine transporter</keyword>
</DOC>